Allogeneic cell therapy for the treatment of solid tumors received fast track designation

A few days ago, Allogene Therapeutics, which focuses on the development of allogeneic CAR-T therapy, announced that the US FDA has granted its innovative therapy ALLO-316 Fast Track designation

Clear cell renal cell carcinoma is a disease with a significant unmet medical need.

The CAR-T therapy targets CD70, which is highly expressed in renal cell carcinoma and limited in other healthy tissues

▲Allogene's R&D pipeline (Image source: Allogene's official website)

Given that ALLO-316 may address an unmet need in this group of patients, the FDA granted Fast Track designation to the therapy

References:

[1] Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma, Retrieved March 11, 2022, from https:// /03/10/2400941/0/en/Allogene-Therapeutics-Receives-FDA-Fast-Track-Designation-for-its-First-Solid-Tumor-Candidate-ALLO-316-in-the-Treatment-of-Renal -Cell-Carcinoma.

(Original abridged)